30 results on '"Holland AE"'
Search Results
2. Using change in 6-minute walk distance to predict survival in progressive pulmonary fibrosis: A promising measure in need of precision.
- Author
-
Holland AE and Dowman L
- Subjects
- Humans, Exercise Test, Exercise Tolerance, Walking, Idiopathic Pulmonary Fibrosis diagnosis
- Published
- 2024
- Full Text
- View/download PDF
3. Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.
- Author
-
Mackintosh JA, Keir G, Troy LK, Holland AE, Grainge C, Chambers DC, Sandford D, Jo HE, Glaspole I, Wilsher M, Goh NSL, Reynolds PN, Chapman S, Mutsaers SE, de Boer S, Webster S, Moodley Y, and Corte TJ
- Subjects
- Humans, New Zealand, Fibrosis, Australia, Pyridones therapeutic use, Idiopathic Pulmonary Fibrosis drug therapy
- Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis., (© 2024 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
- Published
- 2024
- Full Text
- View/download PDF
4. Treatable traits models of care.
- Author
-
McDonald VM and Holland AE
- Subjects
- Humans, Phenotype, Pulmonary Disease, Chronic Obstructive therapy, Asthma therapy, Bronchiectasis, Respiratory Tract Diseases therapy
- Abstract
Treatable traits is a personalized approach to the management of respiratory disease. The approach involves a multidimensional assessment to understand the traits present in individual patients. Traits are phenotypic and endotypic characteristics that can be identified, are clinically relevant and can be successfully treated by therapy to improve clinical outcomes. Identification of traits is followed by individualized and targeted treatment to those traits. First proposed for the management of asthma and chronic obstructive pulmonary disease (COPD) the approach is recommended in many other areas of respiratory and now immunology medicine. Models of care for treatable traits have been proposed in different diseases and health care setting. In asthma and COPD traits are identified in three domains including pulmonary, extrapulmonary and behavioural/lifestyle/risk-factors. In bronchiectasis and interstitial lung disease, a fourth domain of aetiological traits has been proposed. As the core of treatable traits is personalized and individualized medicine; there are several key aspects to treatable traits models of care that should be considered in the delivery of care. These include person centredness, consideration of patients' values, needs and preferences, health literacy and engagement. We review the models of care that have been proposed and provide guidance on the engagement of patients in this approach to care., (© 2023 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
- Published
- 2024
- Full Text
- View/download PDF
5. Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand.
- Author
-
Chang AB, Bell SC, Byrnes CA, Dawkins P, Holland AE, Kennedy E, King PT, Laird P, Mooney S, Morgan L, Parsons M, Poot B, Toombs M, Torzillo PJ, and Grimwood K
- Subjects
- Child, Humans, Adult, Adolescent, New Zealand, Australia, Anti-Bacterial Agents therapeutic use, Bronchiectasis therapy, Bronchiectasis drug therapy, Lung Diseases drug therapy
- Abstract
This position statement, updated from the 2015 guidelines for managing Australian and New Zealand children/adolescents and adults with chronic suppurative lung disease (CSLD) and bronchiectasis, resulted from systematic literature searches by a multi-disciplinary team that included consumers. The main statements are: Diagnose CSLD and bronchiectasis early; this requires awareness of bronchiectasis symptoms and its co-existence with other respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease). Confirm bronchiectasis with a chest computed-tomography scan, using age-appropriate protocols and criteria in children. Undertake a baseline panel of investigations. Assess baseline severity, and health impact, and develop individualized management plans that include a multi-disciplinary approach and coordinated care between healthcare providers. Employ intensive treatment to improve symptom control, reduce exacerbation frequency, preserve lung function, optimize quality-of-life and enhance survival. In children, treatment also aims to optimize lung growth and, when possible, reverse bronchiectasis. Individualize airway clearance techniques (ACTs) taught by respiratory physiotherapists, encourage regular exercise, optimize nutrition, avoid air pollutants and administer vaccines following national schedules. Treat exacerbations with 14-day antibiotic courses based upon lower airway culture results, local antibiotic susceptibility patterns, clinical severity and patient tolerance. Patients with severe exacerbations and/or not responding to outpatient therapy are hospitalized for further treatments, including intravenous antibiotics and intensive ACTs. Eradicate Pseudomonas aeruginosa when newly detected in lower airway cultures. Individualize therapy for long-term antibiotics, inhaled corticosteroids, bronchodilators and mucoactive agents. Ensure ongoing care with 6-monthly monitoring for complications and co-morbidities. Undertake optimal care of under-served peoples, and despite its challenges, delivering best-practice treatment remains the overriding aim., (© 2023 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
- Published
- 2023
- Full Text
- View/download PDF
6. Breathlessness: Remembering the worst of it.
- Author
-
Holland AE and Bondarenko J
- Subjects
- Humans, Dyspnea etiology
- Published
- 2022
- Full Text
- View/download PDF
7. Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia.
- Author
-
Tikellis G, Corte TJ, Teoh AKY, Glaspole IN, Macansh S, and Holland AE
- Subjects
- Australia, Hospitals, Humans, Pulmonologists, Referral and Consultation, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis therapy
- Abstract
Background and Objective: In Australia, little is known about delivery of care for people with idiopathic pulmonary fibrosis (IPF). This study examined the organization of IPF care across Australia, how it aligns with guidance for best practice, and identified barriers and facilitators to best care., Methods: Data on the organization of IPF care in Australia were collected from public hospitals using a study-specific questionnaire between February and July 2020. Semi-structured telephone interviews were conducted with respiratory physicians from around Australia between April and December 2020. Interviews were transcribed verbatim and thematic analysis was undertaken., Results: Almost all hospitals (n = 38, 97%) held multidisciplinary meetings (MDMs) for diagnosing IPF, with 90% of multidisciplinary teams including expert respiratory physicians and radiologists; however, rheumatologists, interstitial lung disease nurses and a histopathologist were often not available. More than 90% of institutions had access to oxygen therapy, pulmonary rehabilitation and advanced care planning, but access to psychological support and clinical trials was limited (53% and 58%, respectively). Fifteen respiratory physicians (27% regional) were interviewed. Approaches to diagnosis, treatment and access to referral services were generally consistent with best practice guidance; however, regional respondents reported barriers related to inadequate staffing, lack of a nurse coordinator, inadequate access to clinical trials and funding models. Telehealth technologies were perceived as facilitators to best care., Conclusion: Clinical management of IPF in Australia generally aligns with best practice guidance, but there may be some inequity of access to specialist services, particularly in regional areas, that should be addressed to ensure optimal care for all., (© 2021 Asian Pacific Society of Respirology.)
- Published
- 2022
- Full Text
- View/download PDF
8. Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand.
- Author
-
Blakey J, Chung LP, McDonald VM, Ruane L, Gornall J, Barton C, Bosnic-Anticevich S, Harrington J, Hew M, Holland AE, Hopkins T, Jayaram L, Reddel H, Upham JW, Gibson PG, and Bardin P
- Subjects
- Administration, Oral, Adolescent, Adrenal Cortex Hormones adverse effects, Adult, Chronic Disease, Humans, New Zealand, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy
- Abstract
Oral corticosteroids (OCS) are frequently used for asthma treatment. This medication is highly effective for both acute and chronic diseases, but evidence indicates that indiscriminate OCS use is common, posing a risk of serious side effects and irreversible harm. There is now an urgent need to introduce OCS stewardship approaches, akin to successful initiatives that optimized appropriate antibiotic usage. The aim of this TSANZ (Thoracic Society of Australia and New Zealand) position paper is to review current knowledge pertaining to OCS use in asthma and then delineate principles of OCS stewardship. Recent evidence indicates overuse and over-reliance on OCS for asthma and that doses >1000 mg prednisolone-equivalent cumulatively are likely to have serious side effects and adverse outcomes. Patient perspectives emphasize the detrimental impacts of OCS-related side effects such as weight gain, insomnia, mood disturbances and skin changes. Improvements in asthma control and prevention of exacerbations can be achieved by improved inhaler technique, adherence to therapy, asthma education, smoking cessation, multidisciplinary review, optimized medications and other strategies. Recently, add-on therapies including novel biological agents and macrolide antibiotics have demonstrated reductions in OCS requirements. Harm reduction may also be achieved through identification and mitigation of predictable adverse effects. OCS stewardship should entail greater awareness of appropriate indications for OCS prescription, risk-benefits of OCS medications, side effects, effective add-on therapies and multidisciplinary review. If implemented, OCS stewardship can ensure that clinicians and patients with asthma are aware that OCS should not be used lightly, while providing reassurance that asthma can be controlled in most people without frequent use of OCS., (© 2021 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
- Published
- 2021
- Full Text
- View/download PDF
9. Physical activity decline is disproportionate to decline in pulmonary physiology in IPF.
- Author
-
Prasad JD, Paul E, Holland AE, Glaspole IN, and Westall GP
- Subjects
- Exercise, Humans, Lung, Quality of Life, Vital Capacity, Idiopathic Pulmonary Fibrosis
- Abstract
Background and Objective: Patients with idiopathic pulmonary fibrosis (IPF) have reduced levels of daily physical activity (DPA); however, little is known about how DPA changes as disease progresses. We aimed to (i) describe change in DPA over 12 months, (ii) analyse its association with conventional markers of disease severity and quality of life and (iii) assess DPA as a prognostic tool., Methods: A total of 54 patients with IPF had DPA monitored at baseline and at 6 and 12 months with a SenseWear armband for 7 consecutive days. Participants completed the Hospital Anxiety and Depression scale, St George's Respiratory Questionnaire and Leicester Cough Questionnaire at each time point and provided clinical data including forced vital capacity (FVC), diffusion capacity of carbon monoxide and 6-min walk distance (6MWD)., Results: Baseline and 12-month daily step count (DSC) were 3887 (395) and 3326 (419), respectively. A significant reduction in DSC (mean = 645 [260], p = 0.02) and total energy expenditure (mean = 486 kJ [188], p = 0.01) was demonstrated at 12 months. The decline in DSC over 12 months was proportionally larger than decline in lung function. Annual change in DPA had weak to moderate correlation with annual change in FVC % predicted and 6MWD (range r = 0.34-0.45). Change in physical activity was not associated with long-term survival., Conclusion: In IPF, decline in DPA over 12 months is significant and disproportionate to decline in pulmonary physiology and may be a useful tool for assessment of disease progression., (© 2021 Asian Pacific Society of Respirology.)
- Published
- 2021
- Full Text
- View/download PDF
10. Attenuation of exertional desaturation and preference for interval exercise compared to continuous exercise in people with interstitial lung disease.
- Author
-
Dowman LM, May AK, Cox NS, Morris NR, Nakazawa A, Parker L, Bondarenko J, and Holland AE
- Subjects
- Exercise Test, Exercise Tolerance, Humans, Exercise, Lung Diseases, Interstitial therapy
- Published
- 2021
- Full Text
- View/download PDF
11. Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.
- Author
-
Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, Symons K, Spencer LM, Reynolds PN, Chapman S, de Boer S, Reddy T, Holland AE, Chambers DC, Glaspole IN, Jo HE, Bleasel JF, Wrobel JP, Dowman L, Parker MJS, Wilsher ML, Goh NSL, Moodley Y, and Keir GJ
- Subjects
- Australia, Clinical Trials as Topic, Connective Tissue Diseases diagnostic imaging, Connective Tissue Diseases pathology, Humans, Lung Diseases, Interstitial diagnostic imaging, Lung Diseases, Interstitial pathology, New Zealand, Connective Tissue Diseases complications, Connective Tissue Diseases diagnosis, Lung Diseases, Interstitial complications, Lung Diseases, Interstitial diagnosis, Societies, Medical
- Abstract
Pulmonary complications in CTD are common and can involve the interstitium, airways, pleura and pulmonary vasculature. ILD can occur in all CTD (CTD-ILD), and may vary from limited, non-progressive lung involvement, to fulminant, life-threatening disease. Given the potential for major adverse outcomes in CTD-ILD, accurate diagnosis, assessment and careful consideration of therapeutic intervention are a priority. Limited data are available to guide management decisions in CTD-ILD. Autoimmune-mediated pulmonary inflammation is considered a key pathobiological pathway in these disorders, and immunosuppressive therapy is generally regarded the cornerstone of treatment for severe and/or progressive CTD-ILD. However, the natural history of CTD-ILD in individual patients can be difficult to predict, and deciding who to treat, when and with what agent can be challenging. Establishing realistic therapeutic goals from both the patient and clinician perspective requires considerable expertise. The document aims to provide a framework for clinicians to aid in the assessment and management of ILD in the major CTD. A suggested approach to diagnosis and monitoring of CTD-ILD and, where available, evidence-based, disease-specific approaches to treatment have been provided., (© 2020 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
- Published
- 2021
- Full Text
- View/download PDF
12. Peer Connect Service for people with pulmonary fibrosis in Australia: Participants' experiences and process evaluation.
- Author
-
Tikellis G, Lee JYT, Corte TJ, Maloney J, Bartlett M, Crawford T, Glaspole IN, Goh N, Herrmann K, Hey-Cunningham AJ, Keir G, Khor YH, Price J, Sandford DG, Spencer L, Teoh A, Walsh J, Webster S, and Holland AE
- Subjects
- Aged, Aged, 80 and over, Australia, Female, Humans, Male, Middle Aged, Surveys and Questionnaires, Telephone, Peer Group, Pulmonary Fibrosis psychology, Social Support
- Abstract
Background and Objective: People living with pulmonary fibrosis (PF) report unmet needs for information and support. Lung Foundation Australia (LFA) have developed the Peer Connect Service to facilitate telephone support for people with PF across Australia. This project documented the experiences of participants and the resources required to support the service., Methods: Consenting participants took part in semi-structured interviews by telephone. Primary peers (peers who agreed to initiate contact) and secondary peers (eligible patients who sought a peer match) were interviewed. Thematic analysis was undertaken by two independent researchers. Data were collected on the number of matches and contacts required to establish each match., Results: Interviews were conducted with 32 participants (16 primary peers, 15 secondary peers and 1 who was both), aged from 53 to 89 years with 56% being male. Major themes included the value of shared experiences, providing mutual support and the importance of shared personal characteristics (e.g. gender and hobbies) in allowing information and emotional support needs to be met. Participants saw face-to-face contact with peers as highly desirable whilst acknowledging the practical difficulties. Primary peers were cognizant that their role was not to provide medical advice but to listen and share experiences. In the 12-month period, 60 peer matches were made, each match requiring a minimum of seven staff contacts., Conclusion: The Peer Connect Service provides a unique opportunity for people with PF to share experiences and offer mutual support. This telephone matching model may be useful in providing peer support for individuals with rare diseases who are geographically dispersed., (© 2020 Asian Pacific Society of Respirology.)
- Published
- 2020
- Full Text
- View/download PDF
13. Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand.
- Author
-
Dummer J, Dobler CC, Holmes M, Chambers D, Yang IA, Parkin L, Smith S, Wark P, Dev A, Hodge S, Dabscheck E, Gooi J, Samuel S, Knowles S, and Holland AE
- Subjects
- Australia, Disease Progression, Humans, Lung Transplantation, New Zealand, Pulmonary Disease, Chronic Obstructive diagnosis, Pulmonary Disease, Chronic Obstructive etiology, Pulmonary Emphysema diagnosis, Pulmonary Emphysema etiology, Plastic Surgery Procedures, alpha 1-Antitrypsin genetics, alpha 1-Antitrypsin Deficiency complications, alpha 1-Antitrypsin Deficiency genetics, Pulmonary Disease, Chronic Obstructive therapy, Pulmonary Emphysema therapy, alpha 1-Antitrypsin therapeutic use, alpha 1-Antitrypsin Deficiency diagnosis, alpha 1-Antitrypsin Deficiency drug therapy
- Abstract
AATD is a common inherited disorder associated with an increased risk of developing pulmonary emphysema and liver disease. Many people with AATD-associated pulmonary emphysema remain undiagnosed and therefore without access to care and counselling specific to the disease. AAT augmentation therapy is available and consists of i.v. infusions of exogenous AAT protein harvested from pooled blood products. Its clinical efficacy has been the subject of some debate and the use of AAT augmentation therapy was recently permitted by regulators in Australia and New Zealand, although treatment is not presently subsidized by the government in either country. The purpose of this position statement is to review the evidence for diagnosis and treatment of AATD-related lung disease with reference to the Australian and New Zealand population. The clinical efficacy and adverse events of AAT augmentation therapy were evaluated by a systematic review, and the GRADE process was employed to move from evidence to recommendation. Other sections address the wide range of issues to be considered in the care of the individual with AATD-related lung disease: when and how to test for AATD, changing diagnostic techniques, monitoring of progression, disease in heterozygous AATD and pharmacological and non-pharmacological therapy including surgical options for severe disease. Consideration is also given to broader issues in AATD that respiratory healthcare staff may encounter: genetic counselling, patient support groups, monitoring for liver disease and the need to establish national registries for people with AATD in Australia and New Zealand., (© 2020 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
- Published
- 2020
- Full Text
- View/download PDF
14. Home-based pulmonary rehabilitation for COPD using minimal resources: An economic analysis.
- Author
-
Burge AT, Holland AE, McDonald CF, Abramson MJ, Hill CJ, Lee AL, Cox NS, Moore R, Nicolson C, O'Halloran P, Lahham A, Gillies R, and Mahal A
- Subjects
- Aged, Aged, 80 and over, Cost-Benefit Analysis, Exercise Therapy, Female, Humans, Male, Middle Aged, Patient Compliance, Prospective Studies, Quality of Life, Quality-Adjusted Life Years, Self Care methods, Treatment Outcome, Walk Test, Ambulatory Care economics, Health Care Costs, Pulmonary Disease, Chronic Obstructive physiopathology, Pulmonary Disease, Chronic Obstructive rehabilitation, Self Care economics
- Abstract
Background and Objective: This study aimed to compare the cost-effectiveness and cost-utility of home and centre-based pulmonary rehabilitation for adults with stable chronic obstructive pulmonary disease (COPD)., Methods: Prospective economic analyses were undertaken from a health system perspective alongside a randomized controlled equivalence trial in which participants referred to pulmonary rehabilitation undertook a standard 8-week outpatient centre-based or a new home-based programme. Participants underwent clinical assessment prior to programme commencement, immediately following completion and 12 months following programme completion. They provided data for utility (quality-adjusted life years (QALY) determined using SF6D (utility scores for health states) calculated from 36-Item Short Form Health Survey version 2) and effectiveness (change in distance walked on 6-min walk test (Δ6MWD) following pulmonary rehabilitation ). Individual-level cost data for the 12 months following programme completion was sourced from healthcare administration and government databases., Results: Between-group mean difference point estimates for cost (-$4497 (95% CI: -$12 250 to $3257), utility (0.025 (-0.038 to 0.086) QALY) and effectiveness (14 m (-11 to 39) Δ6MWD) favoured the home-based group. Cost-utility analyses demonstrated 63% of estimates falling in the dominant southeast quadrant and the probability that the new home-based model was cost-effective at a $0 threshold for willingness to pay was 78%. Results were robust to a range of sensitivity analyses. Programme completion was associated with significantly lower healthcare costs in the following 12 months., Conclusion: Home-based pulmonary rehabilitation provides a cost-effective alternative model for people with COPD who cannot access traditional centre-based programmes., (© 2019 Asian Pacific Society of Respirology.)
- Published
- 2020
- Full Text
- View/download PDF
15. Practical approach to establishing pulmonary rehabilitation for people with non-COPD diagnoses.
- Author
-
Granger CL, Morris NR, and Holland AE
- Subjects
- Bronchiectasis physiopathology, Exercise Therapy, Exercise Tolerance, Humans, Lung physiopathology, Lung Diseases, Interstitial physiopathology, Quality of Life, Bronchiectasis rehabilitation, Hypertension, Pulmonary rehabilitation, Lung Diseases, Interstitial rehabilitation, Lung Neoplasms rehabilitation
- Abstract
Pulmonary rehabilitation is a core aspect in the management of patients with chronic respiratory diseases. This paper describes a practical approach to establishing pulmonary rehabilitation for patients with non-COPD diagnoses using examples from the interstitial lung disease (ILD), pulmonary hypertension (PH), bronchiectasis and lung cancer patient populations. Aspects of pulmonary rehabilitation, including the rationale, patient selection, setting of programmes, patient assessment and training components (both exercise and non-exercise aspects), are discussed for these patient groups. Whilst there are many similarities in the rationale and application of pulmonary rehabilitation across these non-COPD populations, there are also many subtle differences, which are discussed in detail in this paper. With consideration of these factors, pulmonary rehabilitation programmes can be adapted to facilitate the inclusion of respiratory patients with non-COPD diagnoses., (© 2019 Asian Pacific Society of Respirology.)
- Published
- 2019
- Full Text
- View/download PDF
16. Understanding the patient's experience of care in idiopathic pulmonary fibrosis.
- Author
-
Burnett K, Glaspole I, and Holland AE
- Subjects
- Aged, Aged, 80 and over, Comorbidity, Fees and Charges, Female, Health Status, Humans, Idiopathic Pulmonary Fibrosis economics, Interviews as Topic, Male, Middle Aged, Patient Education as Topic standards, Qualitative Research, Self Care, Severity of Illness Index, Travel, Vital Capacity, Health Services Accessibility standards, Idiopathic Pulmonary Fibrosis physiopathology, Idiopathic Pulmonary Fibrosis therapy, Patient Satisfaction, Quality of Health Care
- Published
- 2019
- Full Text
- View/download PDF
17. Pulmonary rehabilitation for chronic obstructive pulmonary disease: Has it peaked?
- Author
-
Holland AE
- Published
- 2019
- Full Text
- View/download PDF
18. Portable oxygen concentrators versus oxygen cylinder during walking in interstitial lung disease: A randomized crossover trial.
- Author
-
Khor YH, McDonald CF, Hazard A, Symons K, Westall G, Glaspole I, Goh NSL, and Holland AE
- Subjects
- Aged, Ambulatory Care methods, Cross-Over Studies, Female, Humans, Lung Diseases, Interstitial diagnosis, Lung Diseases, Interstitial physiopathology, Male, Middle Aged, Outcome and Process Assessment, Health Care, Oxygen Consumption, Physical Exertion physiology, Lung Diseases, Interstitial therapy, Oxygen analysis, Oxygen Inhalation Therapy instrumentation, Oxygen Inhalation Therapy methods, Walking physiology
- Abstract
Background and Objective: Ambulatory oxygen therapy is often provided to patients with interstitial lung disease (ILD). Lightweight portable oxygen concentrators (POCs) provide an alternative to traditional portable systems such as compressed oxygen cylinders; however, their efficacy in patients with ILD has not been assessed. This study aimed to evaluate the clinical performance of three ambulatory oxygen systems (two different POCs and a compressed oxygen cylinder) during 6-min walk tests (6MWTs) in patients with ILD and exertional desaturation., Methods: A total of 20 participants with ILD of varying aetiologies who demonstrated exertional desaturation to <90% on room air during 6MWT were recruited. Each participant performed two 6MWTs while breathing room air. On a subsequent day, two further 6MWTs were performed, in random order: one breathing oxygen via a POC (either the Inogen One G2 POC or the EverGo POC at the setting of 6) and one with a compressed oxygen cylinder (at 5 L/min)., Results: There were no significant differences in nadir oxygen saturation (SpO
2 ) during 6MWTs using different portable oxygen devices (Trial 1: mean SpO2 for Inogen One G2 POC: 82.3 ± 3.5% vs oxygen cylinder: 80.3 ± 2.2%, P = 0.14; Trial 2: mean SpO2 for EverGo POC: 85.7 ± 7.7% vs oxygen cylinder: 86.1 ± 6.1%, P = 0.79). The mean 6-min walk distances were not significantly different among the three devices., Conclusion: The performance of the Inogen One G2 POC and the EverGo POC had comparable performance with that of the compressed oxygen cylinder during walking in patients with ILD and exertional desaturation., (© 2017 Asian Pacific Society of Respirology.)- Published
- 2017
- Full Text
- View/download PDF
19. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.
- Author
-
Tarrant BJ, Le Maitre C, Romero L, Steward R, Button BM, Thompson BR, and Holland AE
- Subjects
- Acetylcysteine pharmacology, Administration, Inhalation, Bronchiectasis physiopathology, Chronic Disease, Deoxyribonuclease I pharmacology, Expectorants pharmacology, Forced Expiratory Volume, Humans, Lung Diseases physiopathology, Mannitol pharmacology, Mesna therapeutic use, Mucociliary Clearance drug effects, Quality of Life, Recombinant Proteins pharmacology, Recombinant Proteins therapeutic use, Saline Solution, Hypertonic pharmacology, Symptom Flare Up, Vital Capacity, Acetylcysteine therapeutic use, Bronchiectasis drug therapy, Deoxyribonuclease I therapeutic use, Expectorants therapeutic use, Lung Diseases drug therapy, Mannitol therapeutic use, Saline Solution, Hypertonic therapeutic use
- Abstract
Inhaled mucoactive agents are used in respiratory disease to improve mucus properties and enhance secretion clearance. The effect of mannitol, recombinant human deoxyribonuclease/dornase alfa (rhDNase) and hypertonic saline (HS) or normal saline (NS) are not well described in chronic lung conditions other than cystic fibrosis (CF). The aim of this review was to determine the benefit and safety of inhaled mucoactive agents outside of CF. We searched Medline, Embase, CINAHL and CENTRAL for randomized controlled trials investigating the effects of mucoactive agents on lung function, adverse events (AEs), health-related quality of life (HRQOL), hospitalization, length of stay, exacerbations, sputum clearance and inflammation. There were detrimental effects of rhDNase in bronchiectasis, with average declines of 1.9-4.3% in forced expiratory volume in 1 s (FEV
1 ) and 3.7-5.4% in forced vital capacity (FVC) (n = 410, two studies), and increased exacerbation risk (relative risk = 1.35, 95% CI = 1.01-1.79 n = 349, one study). Some participants exhibited a reduction in FEV1 (≥10-15%) with mucoactive agents on screening (mannitol = 158 of 1051 participants, rhDNase = 2 of 30, HS = 3 of 80). Most AEs were mild and transient, including bronchospasm, cough and breathlessness. NS eased symptomatic burden in COPD, while NS and HS improved spirometry, HRQOL and sputum burden in non-CF bronchiectasis. Mannitol improved mucociliary clearance in asthma and bronchiectasis, while the effects of N-acetylcysteine were unclear. In chronic lung diseases outside CF, there are small benefits of mannitol, NS and HS. Adverse effects of rhDNase suggest this should not be administered in non-CF bronchiectasis., (© 2017 Asian Pacific Society of Respirology.)- Published
- 2017
- Full Text
- View/download PDF
20. Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia.
- Author
-
Dowman LM, McDonald CF, Bozinovski S, Vlahos R, Gillies R, Pouniotis D, Hill CJ, Goh NSL, and Holland AE
- Subjects
- Aged, Aged, 80 and over, Cross-Over Studies, Dyspnea physiopathology, Exercise physiology, Female, Humans, Hypoxia, Idiopathic Pulmonary Fibrosis complications, Interleukin-10 metabolism, Male, Middle Aged, Muscle, Skeletal metabolism, Muscle, Skeletal physiopathology, Oxidative Stress physiology, Rest, Single-Blind Method, Exercise Tolerance physiology, Idiopathic Pulmonary Fibrosis physiopathology, Idiopathic Pulmonary Fibrosis therapy, Oxygen Inhalation Therapy
- Abstract
Background and Objective: Supplemental oxygen is commonly prescribed in patients with idiopathic pulmonary fibrosis (IPF), although its benefits have not been proven. The aims of this study were to investigate the effect of oxygen on oxidative stress, cytokine production, skeletal muscle metabolism and physiological response to exercise in IPF., Methods: Eleven participants with IPF received either oxygen, at an FiO
2 of 0.50, or compressed air for 1 h at rest and during a cycle endurance test at 85% of peak work rate. Blood samples collected at rest and during exercise were analysed for markers of oxidative stress, skeletal muscle metabolism and cytokines. The protocol was repeated a week later with the alternate intervention., Results: Compared with air, oxygen did not adversely affect biomarker concentrations at rest and significantly improved endurance time (mean difference = 99 ± 81s, P = 0.002), dyspnoea (-1 ± 1 U, P = 0.02), systolic blood pressure (BP; -11 ± 11 mm Hg, P = 0.006), nadir oxyhaemoglobin saturation (SpO2 ; 8 ± 6%, P = 0.001), SpO2 at 2-min (7 ± 6%, P = 0.003) and 5-min isotimes (5 ± 3, P < 0.001) and peak exercise xanthine concentrations (-42 ± 73 µmol/L, P = 0.03). Air significantly increased IL-10 (5 ± 5 pg/mL, P = 0.04) at 2-min isotime. Thiobarbituric acid-reactive substances (TBARs), IL-6, TNF-α, creatine kinase, lactate, heart rate and fatigue did not differ between the two interventions at any time point., Conclusion: In patients with IPF, breathing oxygen at FiO2 of 0.50 at rest seems safe. During exercise, oxygen improves exercise tolerance, alleviates exercise-induced hypoxaemia and reduces dyspnoea. A potential relationship between oxygen administration and improved skeletal muscle metabolism should be explored in future studies., (© 2017 Asian Pacific Society of Respirology.)- Published
- 2017
- Full Text
- View/download PDF
21. Australian and New Zealand Pulmonary Rehabilitation Guidelines.
- Author
-
Alison JA, McKeough ZJ, Johnston K, McNamara RJ, Spencer LM, Jenkins SC, Hill CJ, McDonald VM, Frith P, Cafarella P, Brooke M, Cameron-Tucker HL, Candy S, Cecins N, Chan AS, Dale MT, Dowman LM, Granger C, Halloran S, Jung P, Lee AL, Leung R, Matulick T, Osadnik C, Roberts M, Walsh J, Wootton S, and Holland AE
- Subjects
- Australia, Exercise Tolerance, Hospitalization, Humans, New Zealand, Quality of Life, Guidelines as Topic, Pulmonary Disease, Chronic Obstructive rehabilitation
- Abstract
Background and Objective: The aim of the Pulmonary Rehabilitation Guidelines (Guidelines) is to provide evidence-based recommendations for the practice of pulmonary rehabilitation (PR) specific to Australian and New Zealand healthcare contexts., Methods: The Guideline methodology adhered to the Appraisal of Guidelines for Research and Evaluation (AGREE) II criteria. Nine key questions were constructed in accordance with the PICO (Population, Intervention, Comparator, Outcome) format and reviewed by a COPD consumer group for appropriateness. Systematic reviews were undertaken for each question and recommendations made with the strength of each recommendation based on the GRADE (Gradings of Recommendations, Assessment, Development and Evaluation) criteria. The Guidelines were externally reviewed by a panel of experts., Results: The Guideline panel recommended that patients with mild-to-severe COPD should undergo PR to improve quality of life and exercise capacity and to reduce hospital admissions; that PR could be offered in hospital gyms, community centres or at home and could be provided irrespective of the availability of a structured education programme; that PR should be offered to patients with bronchiectasis, interstitial lung disease and pulmonary hypertension, with the latter in specialized centres. The Guideline panel was unable to make recommendations relating to PR programme length beyond 8 weeks, the optimal model for maintenance after PR, or the use of supplemental oxygen during exercise training. The strength of each recommendation and the quality of the evidence are presented in the summary., Conclusion: The Australian and New Zealand Pulmonary Rehabilitation Guidelines present an evaluation of the evidence for nine PICO questions, with recommendations to provide guidance for clinicians and policymakers., (© 2017 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
- Published
- 2017
- Full Text
- View/download PDF
22. Telerehabilitation for COPD: Could pulmonary rehabilitation deliver on its promise?
- Author
-
Holland AE and Cox NS
- Subjects
- Exercise Therapy, Humans, Pulmonary Disease, Chronic Obstructive rehabilitation, Quality of Life, Exercise Tolerance, Telerehabilitation
- Published
- 2017
- Full Text
- View/download PDF
23. Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline.
- Author
-
Button BM, Wilson C, Dentice R, Cox NS, Middleton A, Tannenbaum E, Bishop J, Cobb R, Burton K, Wood M, Moran F, Black R, Bowen S, Day R, Depiazzi J, Doiron K, Doumit M, Dwyer T, Elliot A, Fuller L, Hall K, Hutchins M, Kerr M, Lee AL, Mans C, O'Connor L, Steward R, Potter A, Rasekaba T, Scoones R, Tarrant B, Ward N, West S, White D, Wilson L, Wood J, and Holland AE
- Subjects
- Australia epidemiology, Consensus, Cystic Fibrosis epidemiology, Cystic Fibrosis physiopathology, Exercise, Guideline Adherence, Health Knowledge, Attitudes, Practice, Humans, Mucociliary Clearance, New Zealand epidemiology, Noninvasive Ventilation, Practice Guidelines as Topic, Quality of Life, Respiratory Function Tests, Respiratory Therapy, Treatment Outcome, Cystic Fibrosis therapy, Patient Compliance statistics & numerical data, Patient Satisfaction statistics & numerical data, Physical Therapy Modalities
- Abstract
Physiotherapy management is a key element of care for people with cystic fibrosis (CF) throughout the lifespan. Although considerable evidence exists to support physiotherapy management of CF, there is documented variation in practice. The aim of this guideline is to optimize the physiotherapy management of people with CF in Australia and New Zealand. A systematic review of the literature in key areas of physiotherapy practice for CF was undertaken. Recommendations were formulated based on National Health and Medical Research Council (Australia) guidelines and considered the quality, quantity and level of the evidence; the consistency of the body of evidence; the likely clinical impact; and applicability to physiotherapy practice in Australia and New Zealand. A total of 30 recommendations were made for airway clearance therapy, inhalation therapy, exercise assessment and training, musculoskeletal management, management of urinary incontinence, managing the newly diagnosed patient with CF, delivery of non-invasive ventilation, and physiotherapy management before and after lung transplantation. These recommendations can be used to underpin the provision of evidence-based physiotherapy care to people with CF in Australia and New Zealand., (© 2016 The Authors Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.)
- Published
- 2016
- Full Text
- View/download PDF
24. Physical activity participation by adults with cystic fibrosis: An observational study.
- Author
-
Cox NS, Alison JA, Button BM, Wilson JW, Morton JM, and Holland AE
- Subjects
- Adult, Exercise Test, Female, Humans, Male, Cystic Fibrosis physiopathology, Exercise physiology, Lung physiopathology, Motor Activity physiology, Quality of Life
- Abstract
Background and Objective: Studies in children with cystic fibrosis (CF) suggest greater physical activity (PA) is associated with a slower rate of decline in respiratory function. In adults with CF, objectively measured PA time and its relationship to long-term clinical outcomes of respiratory function and need for hospitalization are unknown., Methods: PA measured objectively (SenseWear armband), pulmonary function, exercise capacity (Modified Shuttle Test-25) and CF-related quality of life (CFQ-R) were assessed in 65 adults (34 male; mean age 28 years) with CF during a stable phase. A sub-group of these participants undertook additional measurement of PA at hospital discharge for a respiratory exacerbation., Results: Median daily habitual moderate-vigorous PA (MVPA) time was 31-min (IQR:15-53). Participants who accumulated ≥30-min MPVA daily experienced fewer hospital days (P = 0.04), better exercise capacity and higher FEV1 at 12 months (P ≤ 0.001). Daily, fewer females than males accrued ≥30-min MVPA (P = 0.02). Compared with those who did not, participants who accumulated 30-min MVPA in bouts ≥10-min (n = 21) recorded better FEV1 (P = 0.02) and exercise capacity (P = 0.006), and reduced hospital admissions (P = 0.04) and hospital days (P = 0.04) at 12 months. MVPA participation declined significantly 1 month post-hospital discharge (median 12 min (4-34); P = 0.04)., Conclusion: Adults with CF are able to achieve recommended MVPA targets of 30mins/day; however, a significant gender difference in activity time is apparent. Greater time in MVPA is related to more positive clinical outcomes over 12 months. Whether increasing PA levels can improve clinical outcomes in adults with CF warrants further investigation. See Editorial, page 404., (© 2015 Asian Pacific Society of Respirology.)
- Published
- 2016
- Full Text
- View/download PDF
25. Functional capacity in idiopathic pulmonary fibrosis: Looking beyond the lungs.
- Author
-
Holland AE
- Subjects
- Female, Humans, Male, Lung Diseases, Interstitial pathology, Muscle Strength, Muscle, Skeletal pathology
- Published
- 2015
- Full Text
- View/download PDF
26. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease.
- Author
-
Holland AE, Fiore JF Jr, Bell EC, Goh N, Westall G, Symons K, Dowman L, and Glaspole I
- Subjects
- Aged, Australia epidemiology, Comorbidity, Female, Humans, Male, Middle Aged, Prevalence, Risk Assessment, Risk Factors, Walking, Anxiety epidemiology, Depression epidemiology, Dyspnea physiopathology, Dyspnea psychology, Lung Diseases, Interstitial epidemiology, Lung Diseases, Interstitial physiopathology, Lung Diseases, Interstitial psychology, Quality of Life
- Abstract
Background and Objectives: Little is known about the prevalence of anxiety in interstitial lung disease (ILD), and the contributors to depression are not clear. The aim of this study was to determine the prevalence and predictors of anxiety and depression in people with ILD., Methods: One hundred and twenty-four individuals with ILD (age 64 years (standard deviation 12), 48 idiopathic pulmonary fibrosis) participated. Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale to determine likely cases and borderline cases. Associations with demographic data, respiratory function, 6-min walk and Modified Medical Research Council Dyspnoea Scale (MMRC) were examined., Results: The prevalence of anxiety was 31%, with clinically significant anxiety in 12%. Depression was present in 23% of individuals, with 7% having clinically significant depression. Independent predictors of anxiety were a higher MMRC score (P = 0.005, odds ratio (OR) for case 2.60, 95% confidence interval 1.37 to 4.92) and higher nadir SpO2 during walking (P = 0.003, OR for case 1.16, 1.04-1.30). Independent predictors of depression were a higher MMRC score (P = 0.006, case OR 3.84, 1.25-11.78, borderline case OR 2.44, 1.14-5.19) and a greater number of comorbidities (P = 0.003, case OR 2.02, 0.97-4.21, borderline case OR 2.26, 1.30-3.93)., Conclusions: Anxiety and depression are present in a significant minority of individuals with ILD. Dyspnoea and comorbidities are important contributors that may be amenable to intervention., (© 2014 Asian Pacific Society of Respirology.)
- Published
- 2014
- Full Text
- View/download PDF
27. Repeating pulmonary rehabilitation: prevalence, predictors and outcomes.
- Author
-
Heng H, Lee AL, and Holland AE
- Subjects
- Adult, Aged, Aged, 80 and over, Chronic Disease, Cohort Studies, Female, Forced Expiratory Volume, Humans, Lung Diseases, Interstitial complications, Lung Diseases, Interstitial epidemiology, Lung Diseases, Obstructive complications, Lung Diseases, Obstructive epidemiology, Male, Middle Aged, Prevalence, Retreatment, Treatment Outcome, Young Adult, Lung Diseases, Interstitial rehabilitation, Lung Diseases, Obstructive rehabilitation, Respiratory Therapy
- Abstract
Background and Objective: Pulmonary rehabilitation (PR) is a cornerstone of care in chronic respiratory diseases; yet its benefits diminish over time. Repeating PR may be beneficial; however, little is known about the characteristics and outcomes of repeaters. This study aimed to establish the proportion of repeaters, identify characteristics that predict repetition and compare the magnitude of benefits achieved between initial and subsequent programmes., Methods: Patients with stable chronic respiratory diseases who attended PR over a 9-year period were included. Outcome measures included the 6-min walk distance (6MWD) and the Chronic Respiratory Disease Questionnaire-Self-Reported (CRDQ-SR). Independent predictors of repeating were identified., Results: Of 296 patients, 59 (20%) repeated PR, most within 1-3 years. Following the initial programme, repeaters had significant decline in 6MWD (-96.1 ± 84.6 m; P < 0.001) and CRDQ-SR scores (mean decline -3.6 points, range -0.1 to -7.9 points; P < 0.005). The improvement in 6MWD was less in the repeat programme compared with the first (38.4 ± 50.7 m vs 67 ± 40.4 m; P = 0.005), while the change in CRDQ-SR was similar in all domains. A chronic obstructive pulmonary disease diagnosis increased the odds of repeating PR (odds ratio (OR) 4.8; P = 0.005) while improved mastery in the initial programme reduced the odds (OR 0.9; P = 0.033)., Conclusions: One in five patients repeated PR, achieving clinically significant improvements in exercise tolerance and quality of life. Patients with small improvements in disease mastery after initial PR were more likely to repeat the programme and may benefit from earlier intervention or longer duration PR., (© 2014 Asian Pacific Society of Respirology.)
- Published
- 2014
- Full Text
- View/download PDF
28. Reporting of exercise attendance rates for people with chronic obstructive pulmonary disease: a systematic review.
- Author
-
Williams MT, Lewis LK, McKeough Z, Holland AE, Lee A, McNamara R, Phillips A, Wiles L, Knapman L, Wootton S, Milross M, and Effing T
- Subjects
- Data Interpretation, Statistical, Humans, Pulmonary Disease, Chronic Obstructive physiopathology, Quality of Life, Exercise Therapy, Exercise Tolerance physiology, Patient Compliance statistics & numerical data, Pulmonary Disease, Chronic Obstructive rehabilitation
- Abstract
While recommendations for the duration, frequency, mode and intensity of exercise programmes for people with chronic obstructive pulmonary disease (COPD) are specified in consensus statements, criteria for exercise session attendance are less clear. The review questions were: (i) how commonly are a priori criteria and attendance rates reported for people with COPD participating in exercise programmes and (ii) what is the strength of association between attendance and improvements in functional exercise capacity. Database searches identified primary studies of people with COPD participating in exercise or pulmonary rehabilitation programmes of at least 2 weeks duration. Primary outcomes were a priori criteria for attendance, reports of attendance at supervised exercise sessions and mean improvements in functional exercise assessments. Data extraction processes were confirmed prospectively (>80% agreement). Variants of exercise attendance data were described. Linear associations between attendance and improvements in exercise outcomes were explored (Pearson r, P < 0.05). Of the 234 included studies, 86 (37%) reported attendance and 29 (12%) provided a priori criteria for attendance. In the small sample of studies which reported attendance and functional exercise data before and after the intervention, there was little to no relationship between improvements in functional exercise capacity and training volume (prescribed r = -0.03, P = 0.88; attended r = -0.24, P = 0.18). Reporting of exercise programme attendance rates is low and of variable quality for people with COPD. Consistent and explicit reporting of exercise attendance in people with COPD will enable calculation of dose-response relationships and determine the value of a priori exercise attendance criteria., (© 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology.)
- Published
- 2014
- Full Text
- View/download PDF
29. Physiotherapy for cystic fibrosis in Australia: knowledge and acceptance of the Consensus Statement recommendations.
- Author
-
Holland AE and Button BM
- Subjects
- Australia epidemiology, Blood Glucose, Consensus, Data Collection, Exercise, Humans, Physical Therapists, Cystic Fibrosis epidemiology, Cystic Fibrosis therapy, Guideline Adherence, Health Knowledge, Attitudes, Practice, Physical Therapy Modalities
- Abstract
Background and Objective: In 2008, a Consensus Statement was published with the aim of optimizing physiotherapy management for people with cystic fibrosis (CF) in Australia. The aim of this study was to measure knowledge and acceptance of the Consensus Statement recommendations., Methods: All physiotherapists providing treatment to people with CF in Australia were invited to complete a purpose-designed online survey to assess knowledge and uptake of key treatment recommendations., Results: Sixty-eight physiotherapists took part (response rate 49%). Knowledge of treatment recommendations was high for airway clearance (94%) and exercise assessment (76%). Most respondents agreed with these recommendations (airway clearance 97% agreement, exercise 68% agreement). A small number of respondents (18%) correctly identified the current recommendation to segregate patients with different organisms during airway clearance, with most respondents (73%) implementing stricter infection control policies. Low levels of knowledge and agreement were evident for recommendations regarding measurement of blood sugar levels during exercise (36% knowledge and 28% agreement) and delivery of dornase alfa (53% and 65%). Physiotherapists from specialist CF centres were more likely to know the recommendations for blood sugar level measurement during exercise (P = 0.014), dornase alfa (P = 0.001) and non-invasive ventilation (P = 0.07) compared with physiotherapists in other settings., Conclusions: Physiotherapists are aware of treatment recommendations for CF in common areas of practice such as airway clearance and exercise. However, knowledge of recommendations is lower for specialized areas of practice and outside of CF centres. Strategies to improve awareness and uptake of the Consensus Statement among physiotherapists outside of CF centres are required., (© 2012 The Authors. Respirology © 2012 Asian Pacific Society of Respirology.)
- Published
- 2013
- Full Text
- View/download PDF
30. The six-minute walk test in scleroderma: what should we measure and how should we measure it?
- Author
-
Holland AE and Goh NS
- Subjects
- Female, Humans, Male, Exercise Test, Lung Diseases diagnosis, Scleroderma, Systemic diagnosis
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.